One month’s treatment cost and medical insurance support for Nintedanib

Nintedanib (Nintedanib) is a multi-target tyrosine kinase inhibitor mainly used to treat patients with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and certain non-small cell lung cancer. In the domestic market, nintedanib has been approved for marketing by the State Food and Drug Administration and has been included in the national medical insurance directory. This is a great benefit for patients with chronic pulmonary fibrosis diseases and helps improve drug accessibility and reduce economic burden.

According to the current market price, the price of each box of domestic nintedanib original drug (150mg*60 capsules) is usually around 1.20,000~1.5 RMB. Calculated based on the conventional treatment dosage of 150 mg twice a day, approximately 60 pills are needed in a month, which is equivalent to one box of medicine. This means that the monthly treatment cost before reimbursement is about more than 10,000 yuan. This price is still high for ordinary families, especially patients with chronic diseases who require long-term medication.

Fortunately, nintedanib has been included in China’s medical insurance catalog, and eligible patients can use medical insurance to purchase drugs in designated hospitals. Depending on local medical insurance policies, the reimbursement ratio can generally reach 60%~80%. Some areas may also have chronic disease outpatient reimbursement or secondary reimbursement policy support. Based on this estimate, the patient's monthly out-of-pocket expenses after reimbursement may range from 3,000 to 6,000 yuan. The specific amount depends on local policies and the patient's medical insurance type.

In addition, there is also a more affordable Indian imitation version of nintedanib abroad, which sells for about 400 to 500 yuan per box and is suitable for patients with limited financial conditions as an alternative. However, since generic drugs have not yet been officially launched in China, the purchase must be completed through a formal cross-border drug service platform or a qualified international medical intermediary. Patients should pay attention to drug quality and legal compliance issues when choosing, and always use drugs rationally under the guidance of a doctor to ensure the safety and effectiveness of treatment. Overall, as the medical insurance policy gradually improves, the cost burden of nintedanib treatment is expected to be further reduced.

Reference materials:https://www.drugs.com/